CAS 1370351-45-3 | BUPA-010 : Buparlisib - EOS Med Chem
(World's Largest Pharmaceutical Supplier)

CAS 1370351-45-3, known as Semaglutide, is a groundbreaking medication used in the treatment of type 2 diabetes. This peptide-based drug has garnered significant attention for its effectiveness in managing blood sugar levels and improving glycemic control.

Semaglutide belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). It works by mimicking the action of the naturally occurring hormone GLP-1, which stimulates insulin secretion, reduces glucagon release, and slows down gastric emptying. These actions collectively contribute to lower blood glucose levels.

Clinical studies have demonstrated the remarkable efficacy of Semaglutide in the management of type 2 diabetes. When administered once weekly, it has consistently shown superior reductions in HbA1c (a measure of average blood glucose levels) compared to other antidiabetic medications. Additionally, Semaglutide has been associated with weight loss, making it a valuable option for individuals who struggle with both diabetes and obesity.

The safety profile of Semaglutide is generally favorable. Common side effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. However, these are typically transient and diminish over time. Close monitoring of patients during the initial period of treatment helps manage any potential adverse effects.

Beyond its primary use in type 2 diabetes, Semaglutide has also shown promise in other therapeutic areas. It is being investigated for its potential applications in weight management and cardiovascular disease prevention. This highlights the versatility and potential impact of this medication across various aspects of health.

In conclusion, CAS 1370351-45-3, or Semaglutide, represents a significant advancement in the treatment of type 2 diabetes. Its ability to mimic the action of GLP-1 and effectively lower blood glucose levels has made it a game-changer in diabetes management. With ongoing research exploring its potential in weight management and cardiovascular disease prevention, Semaglutide offers hope for improved outcomes for individuals living with diabetes and related conditions.